BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dynavax Technologies Corporation (DVAX) Reports First Quarter 2012 Financial Results


4/30/2012 8:40:05 AM

BERKELEY, CA--(Marketwire - April 27, 2012) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2012, including $106.9 million in cash, cash equivalents and marketable securities at March 31, 2012. This compared to $114 million at December 31, 2011. Total cash for the first quarter of 2012 included $8.6 million in milestone payments from Dynavax's collaborative partners.

Total revenues were $2.4 million for the first quarter 2012, an increase over the $1.7 million reported for the first quarter of 2011 due primarily to the recognition of collaboration revenue under the Company's partnership with AstraZeneca.

Total operating expenses of $18.2 million for the first quarter 2012 decreased from the $19.7 million reported for the first quarter of 2011, resulting primarily from the completion of certain clinical activities for HEPLISAV.

Net loss for the first quarter 2012 of $16.5 million improved from the loss of $18.5 million reported for the same period in 2011.

About HEPLISAV

HEPLISAV™ is an investigational adult hepatitis B vaccine. In earlier Phase 3 trials, HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as 1018 ISS to enhance the immune response.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and earlier protection with fewer doses than currently licensed vaccines. For more information visit www.dynavax.com.

- tables to follow -

                      DYNAVAX TECHNOLOGIES CORPORATION                      
                   CONSOLIDATED STATEMENTS OF OPERATIONS                    
                  (In thousands, except per share amounts)                  
                                (Unaudited)                                 
                                                                            
                                                        Three Months Ended  
                                                             March 31,      
                                                       -------------------- 
                                                          2012       2011   
                                                       ---------  --------- 
Revenues:                                                                   
  Collaboration revenue                                $     929  $     366 
  Grant revenue                                            1,087        889 
  Service and license revenue                                334        489 
                                                       ---------  --------- 
Total revenues                                             2,350      1,744 
                                                                            
Operating expenses:                                                         
  Research and development                                12,405     14,672 
  General and administrative                               5,793      4,754 
  Amortization of intangible assets                            -        245 
                                                       ---------  --------- 
Total operating expenses                                  18,198     19,671 
                                                       ---------  --------- 
                                                                            
Loss from operations                                     (15,848)   (17,927)
                                                                            
Interest income                                               52         33 
Interest expense                                            (587)      (490)
Other expense                                               (122)       (82)
                                                       ---------  --------- 
                                                                            
Net loss                                               $ (16,505) $ (18,466)
                                                       =========  ========= 
                                                                            
Basic and diluted net loss per share                   $   (0.11) $   (0.16)
                                                       =========  ========= 
                                                                            
Shares used to compute basic and diluted net loss per                       
 share                                                   155,431    115,726 
                                                       =========  ========= 
                                                                            
                                                                            
                      DYNAVAX TECHNOLOGIES CORPORATION                      
                         SELECTED BALANCE SHEET DATA                        
                               (In thousands)                               
                                 (Unaudited)                                
                                                                            
                                                   March 31,    December 31,
                                                      2012          2011    
                                                 ------------- -------------
Assets                                                                      
  Cash and cash equivalents and marketable                                  
   securities                                    $     106,881 $     113,961
  Property and equipment, net                            6,962         6,163
  Goodwill                                               2,498         2,312
  Other assets                                           4,335        11,666
                                                 ------------- -------------
Total assets                                     $     120,676 $     134,102
                                                 ============= =============
                                                                            
Liabilities and stockholders'equity                                         
  Accounts payable                               $       2,358 $       2,040
  Accrued liabilities                                    6,932         8,776
  Current portion of deferred revenue                    3,801         4,210
  Non-current portion of deferred revenue                5,849         6,386
  Short-term note payable to Holdings                   13,357        12,810
  Stockholders' equity                                  88,379        99,880
                                                 ------------- -------------
Total liabilities and stockholders' equity       $     120,676 $     134,102
                                                 ============= =============

Contacts:
Jennifer Lew
Vice President, Finance
510-665-7217
Email Contact

Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES